GLPwatch
Nausea
57,736 FAERS reports across 13 drugs
Last updated 2026-07-12 06:04 UTCNausea is the unpleasant feeling of needing to vomit, often described as a queasy or sick sensation in the stomach.
Plain-language definition of the term.
Nausea is listed as an adverse reaction and a warning or caution in the FDA labels for Byetta, Mounjaro, Ozempic, Rybelsus, Saxenda, Soliqua, Trulicity, Victoza, Wegovy, Xultophy, and Zepbound.
AI summary of the sources below.
FAERS report counts (as of 2026Q2) reflect voluntary adverse-event reports and cannot establish causation or true frequency; higher counts often track prescription volume. openFDA FAERS ↗
Reports by drug
| Drug | FAERS reports | Quarter |
|---|---|---|
| Byetta | 12,075 | 2026Q2 |
| Trulicity | 10,025 | 2026Q2 |
| Mounjaro | 8,656 | 2026Q2 |
| Ozempic | 8,652 | 2026Q2 |
| Victoza | 6,244 | 2026Q2 |
| Zepbound | 5,407 | 2026Q2 |
| Bydureon | 2,335 | 2026Q2 |
| Wegovy | 1,925 | 2026Q2 |
| Saxenda | 1,168 | 2026Q2 |
| Rybelsus | 978 | 2026Q2 |
| Soliqua | 150 | 2026Q2 |
| Xultophy | 120 | 2026Q2 |
| Adlyxin | 1 | 2026Q2 |
Mentioned in FDA labels
Research mentioning nausea (15)
- Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
- The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide.
- Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.
- Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects.
- Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis.
- A vitamin B12 conjugate of exendin-4 improves glucose tolerance without associated nausea or hypophagia in rodents.
- Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11.
- Centrally located GLP-1 receptors modulate gastric slow waves and cardiovascular function in ferrets consistent with the induction of nausea.
- Practical Applications of a Nausea and Vomiting Model in the Clinical Development of Additional Doses of Dulaglutide.
- Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.
- Unremitting Nausea Due to Lurasidone After Semaglutide Initiation.
- Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies.
- In Silico Exploration of Therapeutics for GLP-1 Receptor Agonist-Induced Nausea and Their in Vivo Validation in Mice.
- Anatomical evidence links the stomach to the central amygdala, a region responsive to local GLP-1R agonist induced feeding and nausea-like behaviors in male mice.
- Antiemetic effect of acupressure wristbands for GLP-1 medication associated nausea.